| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |